- Home
- ABSI vs FULC Comparison
ABSI vs FULC Comparison
Compare ABSI & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABSI | FULC |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 577.4M | 468.1M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ABSI | FULC |
|---|---|---|
| Price | $3.11 | $10.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $7.98 | ★ $16.38 |
| AVG Volume (30 Days) | ★ 3.6M | 843.0K |
| Earning Date | 11-12-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,815,000.00 | N/A |
| Revenue This Year | $10.72 | N/A |
| Revenue Next Year | $313.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2752.05 |
| 52 Week Low | $2.01 | $2.32 |
| 52 Week High | $6.33 | $15.74 |
Technical Indicators
Market Signals| Indicator | ABSI | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 40.07 | 45.68 |
| Support Level | $3.23 | $9.07 |
| Resistance Level | $4.16 | $10.54 |
| Average True Range (ATR) | 0.22 | 0.74 |
| MACD | -0.06 | -0.16 |
| Stochastic Oscillator | 2.33 | 40.16 |
Price Performance
Historical ComparisonAbout ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.